Treatment Sequencing Strategies in R/R Multiple Myeloma

A panel of myeloma specialists review the case of a 67-year-old patient with multiple myeloma (MM) who received a bispecific antibody.

Following the presentation of a case of a patient with multiple myeloma, the panel have a roundtable discussion on how to approach treatment.

Focusing on treatment paradigms for patients with relapsed/refractory multiple myeloma, the expert panel discusses the role of BCMA-targeted bispecifics and how they might consider sequencing therapies.

Thomas G. Martin, MD, reviews findings from a pooled analysis from MagnetisMM that evaluated elranatamab in patients with relapsed/refractory MM who received prior BCMA-directed therapies.

The panel discusses how they approach treatment selection and sequencing for patients with relapsed/refractory multiple myeloma.

Shaji Kumar, MD, presents the case of a 70-year-old patient with relapsed/refractory multiple myeloma who received CAR T-cell therapy.

Following the presentation of a case of a patient with relapsed/refractory multiple myeloma, the expert panel reviews treatment options.

Shaji Kumar, MD, reviews data from cohort C of CARTITUDE-2 and a real-world study evaluating ide-cel in patients with relapsed/refractory multiple myeloma.

Experts on multiple myeloma outline current challenges in determining the optimal treatment strategy for patients with relapsed/refractory disease who are eligible for bispecifics and CAR T-cell therapy.

Shaji Kumar, MD, reviews data from cohort C of CARTITUDE-2 and a real-world study evaluating ide-cel in patients with relapsed/refractory multiple myeloma.

Experts on multiple myeloma outline current challenges in determining the optimal treatment strategy for patients with relapsed/refractory disease who are eligible for bispecifics and CAR T-cell therapy.

The panel concludes its discussion with key takeaways on unmet needs and evolving treatment paradigms in relapsed/refractory multiple myeloma.